Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behestan Darou omalizumab versus Xolair in moderate to severe asthma
IRCT20250201064582N1Phase 3Recruiting
- Sponsor
- Behestan Darou
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in asthma and allergic asthma (2 arms), sponsored by Behestan Darou. Primary endpoint: Rate of asthma exacerbations over 9 months. Started May 2025; status: recruiting.
02
Drugs
omalizumab
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on IRCT20250201064582N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250201064582N1.